These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 12596216)

  • 1. Antitubercular isoniazid and drug resistance of Mycobacterium tuberculosis--a review.
    Scior T; Meneses Morales I; Garcés Eisele SJ; Domeyer D; Laufer S
    Arch Pharm (Weinheim); 2002; 335(11-12):511-25. PubMed ID: 12596216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystallographic studies on the binding of isonicotinyl-NAD adduct to wild-type and isoniazid resistant 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis.
    Dias MV; Vasconcelos IB; Prado AM; Fadel V; Basso LA; de Azevedo WF; Santos DS
    J Struct Biol; 2007 Sep; 159(3):369-80. PubMed ID: 17588773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystallographic and pre-steady-state kinetics studies on binding of NADH to wild-type and isoniazid-resistant enoyl-ACP(CoA) reductase enzymes from Mycobacterium tuberculosis.
    Oliveira JS; Pereira JH; Canduri F; Rodrigues NC; de Souza ON; de Azevedo WF; Basso LA; Santos DS
    J Mol Biol; 2006 Jun; 359(3):646-66. PubMed ID: 16647717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid.
    Vilchèze C; Wang F; Arai M; Hazbón MH; Colangeli R; Kremer L; Weisbrod TR; Alland D; Sacchettini JC; Jacobs WR
    Nat Med; 2006 Sep; 12(9):1027-9. PubMed ID: 16906155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between isoniazid resistance and superoxide reactivity in mycobacterium tuberculosis KatG.
    Ghiladi RA; Medzihradszky KF; Rusnak FM; Ortiz de Montellano PR
    J Am Chem Soc; 2005 Sep; 127(38):13428-42. PubMed ID: 16173777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid genotypic assays to identify drug-resistant Mycobacterium tuberculosis in South Africa.
    Evans J; Stead MC; Nicol MP; Segal H
    J Antimicrob Chemother; 2009 Jan; 63(1):11-6. PubMed ID: 18940875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular characterization of isoniazid resistance in Mycobacterium tuberculosis: identification of a novel mutation in inhA.
    Leung ET; Ho PL; Yuen KY; Woo WL; Lam TH; Kao RY; Seto WH; Yam WC
    Antimicrob Agents Chemother; 2006 Mar; 50(3):1075-8. PubMed ID: 16495272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid speciation of 15 clinically relevant mycobacteria with simultaneous detection of resistance to rifampin, isoniazid, and streptomycin in Mycobacterium tuberculosis complex.
    Shenai S; Rodrigues C; Mehta A
    Int J Infect Dis; 2009 Jan; 13(1):46-58. PubMed ID: 18565777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of mutations associated with isoniazid and rifampin resistance in Mycobacterium tuberculosis isolates from Samara Region, Russian Federation.
    Nikolayevsky V; Brown T; Balabanova Y; Ruddy M; Fedorin I; Drobniewski F
    J Clin Microbiol; 2004 Oct; 42(10):4498-502. PubMed ID: 15472300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elucidating isoniazid resistance using molecular modeling.
    Wahab HA; Choong YS; Ibrahim P; Sadikun A; Scior T
    J Chem Inf Model; 2009 Jan; 49(1):97-107. PubMed ID: 19067649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple mutations in katG and inhA identified in Thai isoniazid-resistant Mycobacterium tuberculosis isolates.
    Khadka DK; Eampokalap B; Panitchakorn J; Ramasoota P; Khusmith S
    Southeast Asian J Trop Med Public Health; 2007 Mar; 38(2):376-82. PubMed ID: 17539290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of multidrug resistance in Mycobacterium tuberculosis.
    Sekiguchi J; Miyoshi-Akiyama T; Augustynowicz-Kopeć E; Zwolska Z; Kirikae F; Toyota E; Kobayashi I; Morita K; Kudo K; Kato S; Kuratsuji T; Mori T; Kirikae T
    J Clin Microbiol; 2007 Jan; 45(1):179-92. PubMed ID: 17108078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydrogen peroxide-mediated isoniazid activation catalyzed by Mycobacterium tuberculosis catalase-peroxidase (KatG) and its S315T mutant.
    Zhao X; Yu H; Yu S; Wang F; Sacchettini JC; Magliozzo RS
    Biochemistry; 2006 Apr; 45(13):4131-40. PubMed ID: 16566587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison of the proteomes of isoniazid-resistant Mycobacterium tuberculosis strains and isoniazid-susceptible strains].
    Jiang X; Gao F; Zhang WH; Hu ZY; Wang HH
    Zhonghua Jie He He Hu Xi Za Zhi; 2007 Jun; 30(6):427-31. PubMed ID: 17673015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Public health impact of isoniazid-resistant Mycobacterium tuberculosis strains with a mutation at amino-acid position 315 of katG: a decade of experience in The Netherlands.
    van Doorn HR; de Haas PE; Kremer K; Vandenbroucke-Grauls CM; Borgdorff MW; van Soolingen D
    Clin Microbiol Infect; 2006 Aug; 12(8):769-75. PubMed ID: 16842572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment results of rifampicin (RFP) resistant isoniazid (INH) susceptible tuberculosis, a hospital based study].
    Yoshiyama T; Ogata H; Ito K; Aono A; Wada M
    Kekkaku; 2007 Feb; 82(2):95-101. PubMed ID: 17373318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of resistance to anti-tuberculosis drugs in five districts of Equatorial Guinea: rates, risk factors, genotyping of gene mutations and molecular epidemiology.
    Tudó G; González J; Obama R; Rodríguez JM; Franco JR; Espasa M; Simarro PR; Escaramís G; Ascaso C; García A; Jiménez de Anta MT
    Int J Tuberc Lung Dis; 2004 Jan; 8(1):15-22. PubMed ID: 14974741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations responsible for Mycobacterium tuberculosis isoniazid resistance in Italy.
    Rindi L; Bianchi L; Tortoli E; Lari N; Bonanni D; Garzelli C
    Int J Tuberc Lung Dis; 2005 Jan; 9(1):94-7. PubMed ID: 15675557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth.
    Gumbo T; Louie A; Liu W; Ambrose PG; Bhavnani SM; Brown D; Drusano GL
    J Infect Dis; 2007 Jan; 195(2):194-201. PubMed ID: 17191164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.